Hierarchical Cluster Analysis Based on Clinical and Neuropsychological Symptoms Reveals Distinct Subgroups in Fibromyalgia: A Population-Based Cohort Study

被引:1
作者
Maurel, Sara [1 ]
Gimenez-Llort, Lydia [2 ,3 ]
Alegre-Martin, Jose [4 ,5 ]
Castro-Marrero, Jesus [5 ]
机构
[1] Univ Autonoma Barcelona, Dept Med, Barcelona 08193, Spain
[2] Univ Autonoma Barcelona, Sch Med, Dept Psychiat & Forens Med, Barcelona 08193, Spain
[3] Univ Autonoma Barcelona, Inst Neurosci, Barcelona 08193, Spain
[4] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Div Rheumatol, Clin Unit ME,CFS & Long COVID, Barcelona 08035, Spain
[5] Univ Autonoma Barcelona, Vall dHebron Res Inst, Div Rheumatol, Res Unit ME,CFS & Long COVID, Barcelona 08035, Spain
关键词
chronic pain; fibromyalgia; cluster analysis; neuropsychological symptoms; fatigue; mindfulness; CHRONIC PAIN; SPANISH VERSION; IMPACT QUESTIONNAIRE; PERCEIVED INJUSTICE; SCALE; VALIDATION; CLASSIFICATION; ADOLESCENTS; DISABILITY; DEPRESSION;
D O I
10.3390/biomedicines11102867
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fibromyalgia (FM) is a condition characterized by musculoskeletal pain and multiple comorbidities. Our study aimed to identify four clusters of FM patients according to their core clinical symptoms and neuropsychological comorbidities to identify possible therapeutic targets in the condition. We performed a population-based cohort study on 251 adult FM patients referred to primary care according to the 2010 ACR case criteria. Patients were aggregated in clusters by a K-medians hierarchical cluster analysis based on physical and emotional symptoms and neuropsychological variables. Four different clusters were identified in the FM population. Global cluster analysis reported a four-cluster profile (cluster 1: pain, fatigue, poorer sleep quality, stiffness, anxiety/depression and disability at work; cluster 2: injustice, catastrophizing, positive affect and negative affect; cluster 3: mindfulness and acceptance; and cluster 4: surrender). The second analysis on clinical symptoms revealed three distinct subgroups (cluster 1: fatigue, poorer sleep quality, stiffness and difficulties at work; cluster 2: pain; and cluster 3: anxiety and depression). The third analysis of neuropsychological variables provided two opposed subgroups (cluster 1: those with high scores in surrender, injustice, catastrophizing and negative affect, and cluster 2: those with high scores in acceptance, positive affect and mindfulness). These empirical results support models that assume an interaction between neurobiological, psychological and social factors beyond the classical biomedical model. A detailed assessment of such risk and protective factors is critical to differentiate FM subtypes, allowing for further identification of their specific needs and designing tailored personalized therapeutic interventions.
引用
收藏
页数:15
相关论文
共 43 条
  • [1] de Miguel CA, 2010, ACTAS ESP PSIQUIATRI, V38, P108
  • [2] The Pathophysiology, Diagnosis and Treatment of Fibromyalgia
    Arnold, Lesley M.
    [J]. PSYCHIATRIC CLINICS OF NORTH AMERICA, 2010, 33 (02) : 375 - +
  • [3] Classification of fibromyalgia. A systematic review of the literature
    Belenguer, Rafael
    Ramos-Casals, Manuel
    Siso, Antoni
    Rivera, Javier
    [J]. REUMATOLOGIA CLINICA, 2009, 5 (02): : 55 - 62
  • [4] Nishishinya MB, 2006, MED CLIN-BARCELONA, V127, P295
  • [5] Screening to identify patients at risk - Profiles of psychological risk factors for early intervention
    Boersma, K
    Linton, SJ
    [J]. CLINICAL JOURNAL OF PAIN, 2005, 21 (01) : 38 - 43
  • [6] BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728
  • [7] The burden of musculoskeletal diseases in the general population of Spain: results from a national survey
    Carmona, L
    Ballina, J
    Gabriel, R
    Laffon, A
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (11) : 1040 - 1045
  • [8] Casanueva B, 2016, CLIN EXP RHEUMATOL, V34, pS55
  • [9] Juvenile primary fibromyalgia syndrome: A Review- Treatment and Prognosis
    Coles, Maya Levy
    Uziel, Yosef
    [J]. PEDIATRIC RHEUMATOLOGY, 2021, 19 (01)
  • [10] Crofford LJ, 2005, J RHEUMATOL, V32, P41